Japanese multicenter phase II and pharmacokinetic study of rituximab in relapsed or refractory patients with aggressive B-cell lymphoma

Nonparametric Estimation from Incomplete Observations

Kaplan, E. L., & Meier, P. (1992) · Springer series in statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,232 · see citing works

Regression Models and Life-Tables

Cox, D. R. (1972) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1972.tb00899.x · Cited by 39,793 · see citing works

Nonparametric Estimation from Incomplete Observations

Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158 · see citing works

Regression Models and Life-Tables

Cox, D. R. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_37 · Cited by 26,297 · see citing works

Toxicity and response criteria of the Eastern Cooperative Oncology Group

Oken, M. M., Creech, R. H., Tormey, D. C., Horton, J., Davis, T. E., Mcfadden, E. T., & Carbone, P. P. (1982) · American Journal of Clinical Oncology · doi:10.1097/00000421-198212000-00014 · Cited by 11,607 · see citing works

A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group [see comments]

Harris, N. L., Jaffe, E., Stein, H., Pm, B., Jk, C., Cleary, M. L., Delsol, G., Peeters, C., Falini, B., & Gatter, K. C. (1994) · Blood · doi:10.1182/blood.v84.5.1361.1361 · Cited by 6,312 · see citing works

CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma

Coiffier, B., Lepage, E., Brière, J., Herbrecht, R., Tilly, H., Bouabdallah, R., Morel, P., Van Den Neste, E., Salles, G., Gaulard, P., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa011795 · Cited by 5,574 · see citing works

A Predictive Model for Aggressive Non-Hodgkin's Lymphoma

The International Non-Hodgkin's Lymphoma Prognostic Factors Project (1993) · New England Journal of Medicine · doi:10.1056/nejm199309303291402 · Cited by 4,950 · see citing works

Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group.

Cheson, B. D., Horning, S., Coiffier, B., Shipp, M., Fisher, R. I., Connors, J. M., Lister, T., Vose, J., Grillo-López, A., Hagenbeek, A., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.4.1244 · Cited by 3,210 · see citing works

Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.

McLaughlin, P. J., Grillo-López, A. J., Link, B. K., Levy, R., Czuczman, M. S., Williams, M. E., Heyman, M. R., Bence‐Bruckler, I., White, C. A., Cabanillas, F., et al. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.8.2825 · Cited by 2,752 · see citing works

Comparison of a Standard Regimen (CHOP) with Three Intensive Chemotherapy Regimens for Advanced Non-Hodgkin's Lymphoma

Fisher, R. I., Gaynor, E. R., Dahlberg, S., Oken, M. M., Grogan, T. M., Mize, E. M., Glick, J. H., Coltman, C. A., & Miller, T. P. (1993) · New England Journal of Medicine · doi:10.1056/nejm199304083281404 · Cited by 2,148 · see citing works

A Novel DNA Virus (TTV) Associated with Elevated Transaminase Levels in Posttransfusion Hepatitis of Unknown Etiology

Nishizawa, T., Okamoto, H., Konishi, K., Yoshizawa, H., Miyakawa, Y., & Mayumi, M. (1997) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1997.7765 · Cited by 1,230 · see citing works

Characterization of a human B lymphocyte-specific antigen.

Stashenko, P., Nadler, L. M., Hardy, R., & Schlossman, S. F. (1980) · The Journal of Immunology · doi:10.4049/jimmunol.125.4.1678 · Cited by 1,076 · see citing works

One-Sample Multiple Testing Procedure for Phase II Clinical Trials

Fleming, T. R. (1982) · Biometrics · doi:10.2307/2530297 · Cited by 1,004 · see citing works

Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study.

Coiffier, B., Haïoun, C., Ketterer, N., Engert, A., Tilly, H., F., D. D., Johnson, P., Lister, A., Feuring‐Buske, M., Radford, J. A., et al. (1998) · PubMed · doi:10.1182/blood.v92.6.1927 · Cited by 892 · see citing works

Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma

Maloney, D. G., Liles, T. M., Czerwinski, D. K., Waldichuk, C., Rosenberg, J., Grillo-López, A. J., & Levy, R. (1994) · Blood · doi:10.1182/blood.v84.8.2457.2457 · Cited by 761 · see citing works

IDEC-C2B8: results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma.

Maloney, D. G., Grillo-López, A. J., Bodkin, D., White, C. A., Liles, T. M., Royston, I., Varns, C., Rosenberg, J., & Levy, R. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.10.3266 · Cited by 633 · see citing works

Association of serum Rituximab (IDEC–C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin’s lymphoma

Berinstein, N. L., Grillo-López, A. J., White, C. A., Bence‐Bruckler, I., Maloney, D. G., Czuczman, M. S., Green, D., Rosenberg, J., McLaughlin, P. J., & Shen, D. (1998) · Annals of Oncology · doi:10.1023/a:1008416911099 · Cited by 526 · see citing works

European Phase II Study of Rituximab (Chimeric Anti-CD20 Monoclonal Antibody) for Patients With Newly Diagnosed Mantle-Cell Lymphoma and Previously Treated Mantle-Cell Lymphoma, Immunocytoma, and Small B-Cell Lymphocytic Lymphoma

Foran, J. M., Rohatiner, A. Z. S., Cunningham, D., Popescu, R. A., Solal‐Céligny, P., Ghielmini, M. E. G., Coiffier, B., Johnson, P., Gisselbrecht, C., Reyes, F., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.2.317 · Cited by 470 · see citing works

Phase II Study of Rituximab in Combination With CHOP Chemotherapy in Patients With Previously Untreated, Aggressive Non-Hodgkin’s Lymphoma

Vose, J. M., Link, B. K., Grossbard, M. L., Czuczman, M. S., Grillo-López, A. J., Gilman, P. B., Lowe, A., Kunkel, L., & Fisher, R. I. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.2.389 · Cited by 416 · see citing works

Comparison of a Second-Generation Combination Chemotherapeutic Regimen (m-BACOD) with a Standard Regimen (CHOP) for Advanced Diffuse Non-Hodgkin's Lymphoma

Gordon, L. I., Harrington, D. P., Andersen, J., Colgan, J., Glick, J. H., Neiman, R. S., Mann, R. B., Resnick, G. D., Barcos, M. P., Gottlieb, A. J., et al. (1992) · New England Journal of Medicine · doi:10.1056/nejm199211053271903 · Cited by 323 · see citing works

Toxicity Grading Criteria of the Japan Clinical Oncology Group

Tobinai, K., Kohno, A., Shimada, Y., Watanabe, T., Tamura, T., Takeyama, K., Narabayashi, M., Fukutomi, T., Kondo, H., Shimoyama, M., et al. (1993) · Japanese Journal of Clinical Oncology · doi:10.1093/oxfordjournals.jjco.a039642 · Cited by 168 · see citing works

IDEC‐C2B8 anti‐CD20 (Rituximab) immunotherapy in patients with low‐grade non‐Hodgkin's lymphoma and lymphoproliferative disorders: evaluation of response on 48 patients

Nguyen, D. T., AMESS, J. A. L., Doughty, H. A., Hendry, L., & Diamond, L. W. (1999) · European Journal Of Haematology · doi:10.1111/j.1600-0609.1999.tb01725.x · Cited by 162 · see citing works

Feasibility and pharmacokinetic study of a chimeric anti-CD20 monoclonal antibody (IDEC-C2B8, rituximab) in relapsed B-cell lymphoma

Tobinai, K., Kobayashi, Y., Narabayashi, M., Ogura, M., Kagami, Y., MORISHIMA, Y., Ohtsu, T., Igarashi, T., Sasaki, Y., Kinoshita, T., et al. (1998) · Annals of Oncology · doi:10.1023/a:1008265313133 · Cited by 150 · see citing works

Lymphoproliferative diseases in Japan and Western countries: Proceedings of the United States—Japan seminar, September 6 and 7, 1982, in Seattle, Washington

Kadin, M. E., Berard, C. W., Nanba, K., & Wakasa, H. (1983) · Human Pathology · doi:10.1016/s0046-8177(83)80299-8 · Cited by 144 · see citing works

Factors affecting toxicity, response and progression-free survival in relapsed patients with indolent B-cell lymphoma and mantle cell lymphoma treated with rituximab: a Japanese phase II study

Igarashi, T., Kobayashi, Y., Ogura, M., Kinoshita, T., Ohtsu, T., Sasaki, Y., MORISHIMA, Y., Murate, T., Kasai, M., Uike, N., et al. (2002) · Annals of Oncology · doi:10.1093/annonc/mdf155 · Cited by 139 · see citing works

Antibody L26 recognizes an intracellular epitope on the B-cell-associated CD20 antigen.

Mason, D., Comans-Bitter, W. M., Cordell, J. L., Verhoeven, M., & van Dongen, J. J. M. (1990) · Europe PMC (PubMed Central) · Cited by 131 · see citing works

Monoclonal Antibody against PRADl/Cyclin Dl Stains Nuclei of Tumor Cells with Translocation or Amplification at BCL‐1 Locus

Banno, S., Yoshikawa, K., Nakamura, S., Yamamoto, K., Seito, T., Nitta, M., Takahashi, T., Ueda, R., & Seto, M. (1994) · Japanese Journal of Cancer Research · doi:10.1111/j.1349-7006.1994.tb02969.x · Cited by 55 · see citing works

Determination of antibodies to TT virus (TTV) and application to blood donors and patients with post-transfusion non-A to G hepatitis in Japan

Tsuda, F., Okamoto, H., Ukita, M., Tanaka, T., Akahane, Y., Konishi, K., Yoshizawa, H., Miyakawa, Y., & Mayumi, M. (1999) · Journal of Virological Methods · doi:10.1016/s0166-0934(98)00154-2 · Cited by 51 · see citing works

Immunohistochemical Analysis of Cyclin D1 Protein in Hematopoietic Neoplasms with Special Reference to Mantle Cell Lymphoma

Nakamura, S., Seto, M., Banno, S., Suzuki, S., Koshikawa, T., Kitoh, K., Kagami, Y., Ogura, M., Yatabe, Y., Kojima, M., et al. (1994) · Japanese Journal of Cancer Research · doi:10.1111/j.1349-7006.1994.tb02940.x · Cited by 49 · see citing works

Rituximab (anti-CD20 monoclonal antibody) therapy for progressive intermediate-grade non-Hodgkin’s lymphoma after high-dose therapy and autologous peripheral stem cell transplantation

Tsai, D., Moore, H., Hardy, C., Porter, D., Loh, E. Y., Vaughn, D. J., Luger, S. M., Schuster, S., & Stadtmauer, E. A. (1999) · Bone Marrow Transplantation · doi:10.1038/sj.bmt.1701944 · Cited by 35 · see citing works

B-Cell lymphoma of 708 cases in Japan: incidence rates and clinical prognosis according to the REAL classification

Ohshima, K., Suzumiya, J., Sato, K., Kanda, M., Haraoka, S., & Kikuchi, M. (1998) · Cancer Letters · doi:10.1016/s0304-3835(98)00278-x · Cited by 27 · see citing works

Practical Utility of the Revised European‐American Classification of Lymphoid Neoplasms for Japanese Non‐Hodgkin's Lymphomas

Izumo, T., Maseki, N., Mori, S., & Tsuchiya, E. (2000) · Japanese Journal of Cancer Research · doi:10.1111/j.1349-7006.2000.tb00952.x · Cited by 20 · see citing works

Rituximab in B-Cell Hematologic Malignancies: A Review of 20 Years of Clinical Experience

Salles, G., Barrett, M., Foà, R., Maurer, J., O'Brien, S. M., Valente, N., Wenger, M., & Maloney, D. G. (2017) · Advances in Therapy · doi:10.1007/s12325-017-0612-x · Cited by 620 · see citing works

Subcutaneous Administration of Biotherapeutics: An Overview of Current Challenges and Opportunities

Bittner, B., Richter, W., & Schmidt, J. (2018) · BioDrugs · doi:10.1007/s40259-018-0295-0 · Cited by 447 · see citing works

An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin’s lymphoma

Witzig, T. E., Vose, J. M., Zinzani, P. L., Reeder, C. B., Buckstein, R. J., Polikoff, J. A., Bouabdallah, R., Haïoun, C., Tilly, H., Guo, P., et al. (2011) · Annals of Oncology · doi:10.1093/annonc/mdq626 · Cited by 392 · see citing works

Review of therapeutic drug monitoring of anticancer drugs part two – Targeted therapies

Widmer, N., Bardin, C., Chatelut, É., Paci, A., Beijnen, J. H., Levêque, D., Veal, G. J., & Astier, A. (2014) · European Journal of Cancer · doi:10.1016/j.ejca.2014.04.015 · Cited by 299 · see citing works

The role of sex and weight on rituximab clearance and serum elimination half-life in elderly patients with DLBCL

Müller, C., Murawski, N., Wiesen, M. H. J., Held, G., Poeschel, V., Zeynalova, S., Wenger, M., Nickenig, C., Peter, N., Lengfelder, E., et al. (2012) · Blood · doi:10.1182/blood-2011-09-380949 · Cited by 243 · see citing works

Evidence for Therapeutic Drug Monitoring of Targeted Anticancer Therapies

Gao, B., Yeap, S. H., Clements, A., Balakrishnar, B., Wong, M. K., & Gurney, H. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.43.5362 · Cited by 205 · see citing works

Cancer Immunotherapy

Dillman, R. O. (2011) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1089/cbr.2010.0902 · Cited by 156 · see citing works

Suboptimal dosing of rituximab in male and female patients with DLBCL

Pfreundschuh, M. G., Müller, C., Zeynalova, S., Kuhnt, E., Wiesen, M. H. J., Held, G., Rixecker, T., Poeschel, V., Zwick, C., Reiser, M., et al. (2013) · Blood · doi:10.1182/blood-2013-07-517037 · Cited by 142 · see citing works

Reactivation of hepatitis B virus with rituximab

Tsutsumi, Y., Kanamori, H., Mori, A., Tanaka, J., Asaka, M., Imamura, M., & Masauzi, N. (2005) · Expert Opinion on Drug Safety · doi:10.1517/14740338.4.3.599 · Cited by 135 · see citing works

Multicenter phase 1 trial of intraventricular immunochemotherapy in recurrent CNS lymphoma

Rubenstein, J. L., Li, J., Chen, L., Advani, R. H., Drappatz, J., Gerstner, E. R., Batchelor, T. T., Krouwer, H. G. J., Hwang, J. Q., Auerback, G. M., et al. (2012) · Blood · doi:10.1182/blood-2012-07-440974 · Cited by 123 · see citing works

Efficacy and safety of subcutaneous rituximab versus intravenous rituximab for first-line treatment of follicular lymphoma (SABRINA): a randomised, open-label, phase 3 trial

Davies, A., Merli, F., Mihaljević, B., Mercadal, S., Siritanaratkul, N., Solal-Céligny, P., Boehnke, A., Berge, C., Genevray, M., Zharkov, A., et al. (2017) · The Lancet Haematology · doi:10.1016/s2352-3026(17)30078-9 · Cited by 125 · see citing works

Pharmacokinetics of rituximab and its clinical use: Thought for the best use?

Cartron, G., Blasco, H., Paintaud, G., Watier, H., & Guellec, C. B. (2007) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2006.09.004 · Cited by 122 · see citing works

A phase I/II study of galiximab (an anti-CD80 monoclonal antibody) in combination with rituximab for relapsed or refractory, follicular lymphoma

Leonard, J. P., Friedberg, J. W., Younes, A., Fisher, D. C., Gordon, L. I., Moore, J. O., Czuczman, M. S., Miller, T. P., Stiff, P. J., Cheson, B. D., et al. (2007) · Annals of Oncology · doi:10.1093/annonc/mdm114 · Cited by 116 · see citing works

Pharmacokinetics and safety of subcutaneous rituximab in follicular lymphoma (SABRINA): stage 1 analysis of a randomised phase 3 study

Davies, A., Merli, F., Mihaljevic, B., Siritanaratkul, N., Solal-Céligny, P., Barrett, M., Berge, C., Bittner, B., Boehnke, A., McIntyre, C., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70005-1 · Cited by 114 · see citing works

Cancer Chemotherapy: The Case for Therapeutic Drug Monitoring

Knezevic, C. E., & Clarke, W. A. (2019) · Therapeutic Drug Monitoring · doi:10.1097/ftd.0000000000000701 · Cited by 111 · see citing works

High-Dose Celecoxib and Metronomic “Low-dose” Cyclophosphamide Is an Effective and Safe Therapy in Patients with Relapsed and Refractory Aggressive Histology Non–Hodgkin's Lymphoma

Buckstein, R. J., Kerbel, R. S., Shaked, Y., Nayar, R., Foden, C., Turner, R. A., Lee, C. R., Taylor, D., Zhang, L., Man, S., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0474 · Cited by 110 · see citing works

Rituximab pharmacokinetics during the management of acute idiopathic thrombotic thrombocytopenic purpura

McDonald, V., Manns, K., Mackie, I. J., Machin, S. J., & Scully, M. (2010) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2010.03818.x · Cited by 109 · see citing works

Pruritus in patients treated with targeted cancer therapies: Systematic review and meta-analysis

Ensslin, C. J., Rosen, A. C., Wu, S., & Lacouture, M. E. (2013) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2013.06.038 · Cited by 101 · see citing works

Rituximab exposure is influenced by baseline metabolic tumor volume and predicts outcome of DLBCL patients: a Lymphoma Study Association report

Tout, M., Casasnovas, O., Meignan, M. A., Lamy, T., Morschhauser, F., Salles, G., Gyan, E., Haïoun, C., Mercier, M., Feugier, P., et al. (2017) · Blood · doi:10.1182/blood-2016-10-744292 · Cited by 98 · see citing works

Pharmacokinetic Behavior of Rituximab

Regazzi, M. B., Iacona, I., Avanzini, M. A., Arcaini, L., Merlini, G., Perfetti, V., Zaja, F. F., Montagna, M., Morra, E., & Lazzarino, M. (2005) · Therapeutic Drug Monitoring · doi:10.1097/01.ftd.0000184162.60197.c1 · Cited by 92 · see citing works

Therapeutic drug monitoring of monoclonal antibodies in inflammatory and malignant disease: Translating TNF‐α experience to oncology

Munnink, T. H. O., Henstra, M. J., Segerink, L., Movig, K. L. L., & Brummelhuis-Visser, P. (2015) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.211 · Cited by 91 · see citing works

Ten years of rituximab in NHL

Winter, M. C., & Hancock, B. W. (2009) · Expert Opinion on Drug Safety · doi:10.1517/14740330902750114 · Cited by 89 · see citing works

Population pharmacokinetics of rituximab with or without plasmapheresis in kidney patients with antibody‐mediated disease

Puisset, F., White‐Koning, M., Kamar, N., Huart, A., Haberer, F., Blasco, H., Guellec, C. B., Lafont, T., Grand, A., Rostaing, L. P. E., et al. (2013) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12098 · Cited by 81 · see citing works

Population Pharmacokinetics of Rituximab in Patients With Chronic Lymphocytic Leukemia

Li, J., Zhi, J., Wenger, M., Valente, N., Dmoszyńska, A., Robak, T., Mangat, R., Joshi, A., & Visich, J. E. (2012) · The Journal of Clinical Pharmacology · doi:10.1177/0091270011430506 · Cited by 79 · see citing works

Subcutaneous immunoglobulin in lymphoproliferative disorders and rituximab-related secondary hypogammaglobulinemia: a single-center experience in 61 patients

Compagno, N., Cinetto, F., Semenzato, G., & Agostini, C. (2014) · Haematologica · doi:10.3324/haematol.2013.101261 · Cited by 72 · see citing works

Everolimus in combination with rituximab induces complete responses in heavily pretreated diffuse large B-cell lymphoma

Barnes, J. A., Jacobsen, E. D., Feng, Y., Freedman, A. S., Hochberg, E. P., LaCasce, A. S., Armand, P. A., Joyce, R., Sohani, A. R., Rodig, S. J., et al. (2012) · Haematologica · doi:10.3324/haematol.2012.075184 · Cited by 67 · see citing works

Subcutaneous Rituximab for the Treatment of B-Cell Hematologic Malignancies: A Review of the Scientific Rationale and Clinical Development

Davies, A. J., Berge, C., Boehnke, A., Dadabhoy, A., Lugtenburg, P. J., Rule, S. A., Rummel, M., McIntyre, C., Smith, R. B. W., & Badoux, X. C. A. (2017) · Advances in Therapy · doi:10.1007/s12325-017-0610-z · Cited by 67 · see citing works

Use of rituximab in diffuse large B‐cell lymphoma in the salvage setting

Gisselbrecht, C. (2008) · British Journal of Haematology · doi:10.1111/j.1365-2141.2008.07383.x · Cited by 62 · see citing works

Population pharmacokinetics of rituximab in patients with diffuse large B‐cell lymphoma and association with clinical outcome

Rožman, S., Grabnar, I., Novaković, S., Mrhar, A., & Novaković, B. J. (2017) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.13271 · Cited by 58 · see citing works

Pharmacokinetic/pharmacodynamic relationship of therapeutic monoclonal antibodies used in oncology: Part 1, monoclonal antibodies, antibody-drug conjugates and bispecific T-cell engagers

Paci, A., Desnoyer, A., Delahousse, J., Blondel, L., Maritaz, C., Chaput, N., Mir, O., & Broutin, S. (2020) · European Journal of Cancer · doi:10.1016/j.ejca.2020.01.005 · Cited by 57 · see citing works

Bioanalytical methods for the quantification of therapeutic monoclonal antibodies and their application in clinical pharmacokinetic studies

Damen, C. W. N., Schellens, J. H. M., & Beijnen, J. H. (2009) · Human Antibodies · doi:10.3233/hab-2009-0206 · Cited by 53 · see citing works

Pharmacokinetics of therapeutic monoclonal antibodies used in oncology.

Levêque, D., Wisniewski, S., & Jehl, F. (2005) · PubMed · Cited by 47 · see citing works

Pharmacokinetics, safety, and efficacy of subcutaneous versus intravenous rituximab plus chemotherapy as treatment for chronic lymphocytic leukaemia (SAWYER): a phase 1b, open-label, randomised controlled non-inferiority trial

Assouline, S. E., Buccheri, V., Delmer, A. J., Gaïdano, G., Trněný, M., Berthillon, N., Brewster, M., Catalani, O., Li, S., McIntyre, C., et al. (2016) · The Lancet Haematology · doi:10.1016/s2352-3026(16)00004-1 · Cited by 45 · see citing works

Pharmacokinetics and pharmacokinetic/pharmacodynamic associations of ofatumumab, a human monoclonal CD20 antibody, in patients with relapsed or refractory chronic lymphocytic leukaemia: a phase 1–2 study

Coiffier, B., Losic, N., Rønn, B. B., Leprêtre, S., Pedersen, L. M., Gadeberg, O., Frederiksen, H., van Oers, M. H. J., Wooldridge, J. E., Kloczko, J. S., et al. (2010) · British Journal of Haematology · doi:10.1111/j.1365-2141.2010.08193.x · Cited by 39 · see citing works

Rationale for optimal obinutuzumab/GA101 dosing regimen in B-cell non-Hodgkin lymphoma

Cartron, G., Hourcade‐Potelleret, F., Morschhauser, F., Salles, G., Wenger, M., Truppel-Hartmann, A., & Carlile, D. J. (2015) · Haematologica · doi:10.3324/haematol.2015.133421 · Cited by 36 · see citing works

CD19 chimeric antigen receptor (CD19 CAR)-redirected adoptive T-cell immunotherapy for the treatment of relapsed or refractory B-cell Non-Hodgkin's Lymphomas.

Onea, A. S., & Jazirehi, A. R. (2016) · PubMed Central · Cited by 35 · see citing works

Mogamulizumab for the treatment of T-cell lymphoma

Makita, S., & Tobinai, K. (2017) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2017.1347634 · Cited by 35 · see citing works

Pharmacokinetics of rituximab associated with CHOP chemotherapy in B‐cell non‐Hodgkin lymphoma

Blasco, H., Chatelut, É., Bretagne, I. B., Congy‐Jolivet, N., & Guellec, C. B. (2009) · Fundamental and Clinical Pharmacology · doi:10.1111/j.1472-8206.2009.00714.x · Cited by 30 · see citing works

Influence of FCGR3A-158V/F Genotype and Baseline CD20 Antigen Count on Target-Mediated Elimination of Rituximab in Patients with Chronic Lymphocytic Leukemia: A Study of FILO Group

Tout, M., Gagez, A.-L., Leprêtre, S., Gouilleux‐Gruart, V., Azzopardi, N., Delmer, A. J., Mercier, M., Ysebaert, L., Laribi, K., Gonzalez, H., et al. (2016) · Clinical Pharmacokinetics · doi:10.1007/s40262-016-0470-8 · Cited by 30 · see citing works

A randomized phase 2/3 study of R-CHOP vs CHOP combined with dose-dense rituximab for DLBCL: the JCOG0601 trial

Ohmachi, K., Kinoshita, T., Tobinai, K., Ogawa, G., Mizutani, T., Yamauchi, N., Fukuhara, N., Uchida, T., Yamamoto, K., Miyazaki, K., et al. (2021) · Blood Advances · doi:10.1182/bloodadvances.2020002567 · Cited by 29 · see citing works

Phase I study of LY2469298, an Fc‐engineered humanized anti‐CD20 antibody, in patients with relapsed or refractory follicular lymphoma

Tobinai, K., Ogura, M., Kobayashi, Y., Uchida, T., Watanabe, T., Oyama, T., Maruyama, D., Suzuki, T., Mori, M., Kasai, M., et al. (2010) · Cancer Science · doi:10.1111/j.1349-7006.2010.01809.x · Cited by 29 · see citing works

Cross-Validation of a Multiplex LC-MS/MS Method for Assaying mAbs Plasma Levels in Patients with Cancer: A GPCO-UNICANCER Study

Marin, C., Khoudour, N., Millet, A., Lebert, D., Bros, P., Thomas, F., Ternant, D., Lacarelle, B., Guitton, J., Ciccolini, J., et al. (2021) · Pharmaceuticals · doi:10.3390/ph14080796 · Cited by 28 · see citing works

Lymphoma Study Group of JCOG

Tsukasaki, K., Tobinai, K., Hotta, T., & Shimoyama, M. (2011) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyr168 · Cited by 27 · see citing works

A phase I study of PRO131921, a novel anti-CD20 monoclonal antibody in patients with relapsed/refractory CD20+ indolent NHL: Correlation between clinical responses and AUC pharmacokinetics

Casulo, C., Vose, J. M., Ho, W., Kahl, B. S., Brunvand, M. W., Goy, A. H., Kasamon, Y. L., Cheson, B. D., & Friedberg, J. W. (2014) · Clinical Immunology · doi:10.1016/j.clim.2014.06.005 · Cited by 26 · see citing works

Monoclonal Antibody Capture and Analysis Using Porous Membranes Containing Immobilized Peptide Mimotopes

Liu, W., Bennett, A. L., Ning, W., Tan, H. Y., Berwanger, J. D., Zeng, X., & Bruening, M. L. (2018) · Analytical Chemistry · doi:10.1021/acs.analchem.8b03183 · Cited by 25 · see citing works

Outcomes of primary thyroid non-Hodgkin’s Lymphoma

Čolović, M., Matić, S., Kryeziu, E., Tomin, D., Čolović, N., & Atkinson, H. D. (2007) · Medical Oncology · doi:10.1007/bf02698041 · Cited by 25 · see citing works

Model‐based design of rituximab dosage optimization in follicular non‐Hodgkin's lymphoma

Ternant, D., Cartron, G., Hénin, É., Tod, M. M., Girard, P., & Paintaud, G. (2011) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2011.04125.x · Cited by 24 · see citing works

Identification of patients with indolent B cell lymphoma sensitive to rituximab monotherapy

Cornec, D., Tempescul, A., Querellou, S., Hutin, P., Pers, J., Jamin, C., Bendaoud, B., Berthou, C., Renaudineau, Y., & Youinou, P. (2011) · Annals of Hematology · doi:10.1007/s00277-011-1369-y · Cited by 23 · see citing works

Rituximab in chronic lymphocytic leukemia

James, D. F., & Kipps, T. J. (2011) · Advances in Therapy · doi:10.1007/s12325-011-0032-2 · Cited by 21 · see citing works

Rituximab monotherapy with eight weekly infusions for relapsed or refractory patients with indolent B cell non‐Hodgkin lymphoma mostly pretreated with rituximab: A multicenter phase II study

Tobinai, K., Igarashi, T., Itoh, K., Kurosawa, M., Nagai, H., Hiraoka, A., Kinoshita, T., Uike, N., Ogura, M., Nawano, S., et al. (2011) · Cancer Science · doi:10.1111/j.1349-7006.2011.02001.x · Cited by 20 · see citing works

Monoclonal Antibody Monitoring: Clinically Relevant Aspects, A Systematic Critical Review

Regazzi, M. B., Golay, J., & Molinaro, M. (2019) · Therapeutic Drug Monitoring · doi:10.1097/ftd.0000000000000681 · Cited by 19 · see citing works

Improved therapeutic outcomes of DLBCL after introduction of rituximab in Korean patients

Lymphoma Study Division of the Korean Cancer Study Group, Park, Y. H., Lee, J. J., Ryu, M., Kim, S. Y., Kim, D. H., Do, Y. R., Lee, K. H., Oh, S. J., Kim, Y. K., et al. (2006) · Annals of Hematology · doi:10.1007/s00277-005-0060-6 · Cited by 19 · see citing works

Clinical Trials for Malignant Lymphoma in Japan

Tobinai, K., & Hotta, T. (2004) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyh060 · Cited by 18 · see citing works

Pixantrone–Rituximab Versus Gemcitabine–Rituximab In Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma

Belada, D., Georgiev, P., Dakhil, S. R., Inhorn, L. F., Andorsky, D. J., Beck, J. T., Quick, D. P., Pettengell, R., Daly, R., Dean, J. P., et al. (2016) · Future Oncology · doi:10.2217/fon-2016-0137 · Cited by 17 · see citing works

Rituximab in combination with CHOP chemotherapy for the treatment of diffuse large B cell lymphoma in Chinese patients

Li, J., Wang, L., Shen, Y., Xia, Z. G., Chen, Y., Chen, Q. S., Chen, Y., Zeng, X., You, J. H., Qian, Y., et al. (2007) · Annals of Hematology · doi:10.1007/s00277-007-0320-8 · Cited by 17 · see citing works

Weekly rituximab consolidation following four cycles of R‐ CHOP induction chemotherapy in very elderly patients with diffuse large B‐cell lymphoma: Consortium for improving survival of lymphoma study ( CISL )

Jung, S., Lee, J., Kim, W. S., Lee, W., Do, Y. R., Oh, S. Y., Kim, M. K., Mun, Y., Shin, H., Kwak, J., et al. (2014) · European Journal Of Haematology · doi:10.1111/ejh.12459 · Cited by 16 · see citing works

Prevention of Hepatitis B Virus Reactivation Under Rituximab Therapy

Tsutsumi, Y., Yamamoto, Y., Tanaka, J., Asaka, M., Imamura, M., & Masauzi, N. (2009) · Immunotherapy · doi:10.2217/imt.09.59 · Cited by 15 · see citing works

Rituximab alone was effective for the treatment of a diffuse large B-cell lymphoma associated with hemophagocytic syndrome

Sano, T., Sakai, H., Takimoto, K., & Ohno, H. (2007) · International Journal of Clinical Oncology · doi:10.1007/s10147-006-0627-9 · Cited by 15 · see citing works

The Influence of Different Disease States on Rituximab Pharmacokinetics

Wang, X., Du, W., Zhang, X., & Li, P. (2020) · Current Drug Metabolism · doi:10.2174/1389200221666200719004035 · Cited by 14 · see citing works

Subcutaneous Rituximab with Recombinant Human Hyaluronidase in the Treatment of Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia

Hill, S. L., & Davies, A. J. (2018) · Future Oncology · doi:10.2217/fon-2017-0574 · Cited by 12 · see citing works

A Systematic Review of the Clinical Efficacy of Treatments in Relapsed or Refractory Diffuse Large B Cell Lymphoma

Thuresson, P.-O., Velde, N. V., Gupta, P., & Talbot, J. (2020) · Advances in Therapy · doi:10.1007/s12325-020-01507-7 · Cited by 12 · see citing works

Effects of ultrasound on apoptosis induced by anti-CD20 antibody in CD20-positive B lymphoma cells

Danno, D., Kanno, M., Fujimoto, S., Feril, L. B., Kondo, T., & Nakamura, S. (2007) · Ultrasonics Sonochemistry · doi:10.1016/j.ultsonch.2007.08.004 · Cited by 12 · see citing works

Phase I study of chimeric anti-CD20 monoclonal antibody in Chinese patients with CD20-positive non-Hodgkin’s lymphoma

Gui, L., Han, X., He, X., Song, Y., Yao, J., Yang, J., Liu, P., Qin, Y., Zhang, S., Zhang, W., et al. (2016) · Chinese Journal of Cancer Research · doi:10.21147/j.issn.1000-9604.2016.02.07 · Cited by 10 · see citing works

Quantitative Clinical Pharmacology Supports the Bridging From i.v. Dosing and Approval of s.c. Rituximab in B‐Cell Hematological Malignancies

Jamois, C., Gibiansky, E., Gibiansky, L. V., Chavanne, C., Morcos, P. N., McIntyre, C., Barrett, M., Lundberg, L., Zharkov, A., Boehnke, A., et al. (2021) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.2308 · Cited by 9 · see citing works

Monoclonal antibody therapy

Dillman, R. O. (2009) · Springer eBooks · doi:10.1007/978-90-481-2289-9_10 · Cited by 9 · see citing works

The effect of adding rituximab to CHOP-based therapy on clinical outcomes for Japanese patients with diffuse large B-cell lymphoma: a propensity score matching analysis

for the West-Japan Hematology and Oncology Group (West-JHOG), Nishimori, H., Matsuo, K., Maeda, Y., Nawa, Y., Sunami, K., Togitani, K., Takimoto, H., Hiramatsu, Y., Kiguchi, T., et al. (2009) · International Journal of Hematology · doi:10.1007/s12185-009-0259-8 · Cited by 9 · see citing works

Safety and efficacy of ofatumumab in patients with fludarabine and alemtuzumab refractory chronic lymphocytic leukaemia

Dyer, M. J. S. (2012) · Therapeutic Advances in Hematology · doi:10.1177/2040620712445329 · Cited by 9 · see citing works

Selection of clinically relevant drug concentrations for in vitro studies of candidates drugs for cancer repurposing: a proposal

Robles-Bañuelos, B., Romo‐Pérez, A., Domínguez-Gómez, G., Chávez-Blanco, A. D., González‐Fierro, A., & Dueñas‐González, A. (2023) · Clinical & Translational Oncology · doi:10.1007/s12094-023-03352-w · Cited by 8 · see citing works

Single-Agent and Associated Therapies with Monoclonal Antibodies: What About Follicular Lymphoma?

Cancemi, G., Campo, C., Caserta, S., Rizzotti, I., & Mannina, D. (2025) · Cancers · doi:10.3390/cancers17101602 · Cited by 8 · see citing works

Bendamustine plus rituximab in Japanese patients with relapsed or refractory diffuse large B-cell lymphoma

Murayama, K., Kiguchi, T., Izutsu, K., Kameoka, Y., Hidaka, M., Kato, H., Rai, S., Kuroda, J., Ishizawa, K., Ichikawa, S., et al. (2022) · Annals of Hematology · doi:10.1007/s00277-022-04801-2 · Cited by 8 · see citing works

Rituximab plus ASHAP for the treatment of patients with relapsed or refractory aggressive non-Hodgkin’s lymphoma: a single-centre study of 20 patients

Aydin, S., Dührsen, U., & Nückel, H. (2007) · Annals of Hematology · doi:10.1007/s00277-006-0243-9 · Cited by 8 · see citing works

Modeling combined chemo- and immunotherapy of high-grade non-Hodgkin lymphoma

Roesch, K., Scholz, M. R., & Hasenclever, D. (2015) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2015.1110746 · Cited by 8 · see citing works

Role of obinutuzumab exposure on clinical outcome of follicular lymphoma treated with first‐line immunochemotherapy

Jamois, C., Gibiansky, E., Gibiansky, L. V., Buchheit, V., Sahin, D., Cartron, G., Marcus, R. E., Hiddemann, W., Seymour, J. F., Strefford, J. C., et al. (2019) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.13920 · Cited by 8 · see citing works

Low initial trough concentration of rituximab is associated with unsatisfactory response of first-line R-CHOP treatment in patients with follicular lymphoma with grade 1/2

Liu, S., Huang, H., Chen, R., Wang, Z., Guan, Y.-P., Chen, P., Fang, X., Chen, Z., Guan, S., Zhu, X., et al. (2020) · Acta Pharmacologica Sinica · doi:10.1038/s41401-020-0479-2 · Cited by 7 · see citing works

Rituximab exposure‐response in triweekly R‐CHOP treatment in DLBCL: A loading dose is recommended to improve clinical outcomes

Liu, S., Wang, Z., Chen, R., Huang, H., Wang, X., Chen, P., Guan, Y., Fang, X., Guan, S., Huang, H., et al. (2021) · Clinical and Translational Science · doi:10.1111/cts.13186 · Cited by 6 · see citing works

A multi-center, open-label, randomized, parallel-controlled phase II study comparing pharmacokinetic, pharmacodynamics and safety of ripertamab (SCT400) to rituximab (MabThera� in patients with CD20-positive B-cell non-Hodgkin lymphoma

Han, X., Zhang, M., Wang, H., Zhang, Q., Li, W., Hao, M.-W., Gao, Y., Jin, J., Ren, H., Tang, Y., et al. (2022) · Chinese Journal of Cancer Research · doi:10.21147/j.issn.1000-9604.2022.06.08 · Cited by 6 · see citing works

Estudio de adecuación a la ficha técnica, efectividad, seguridad y coste del rituximab en un hospital de tercer nivel

García, M., Feijoo, M. A. F., & Hernández, M. Á. C. (2009) · Farmacia Hospitalaria · doi:10.1016/s1130-6343(09)72973-3 · Cited by 6 · see citing works

Phase I Dose Escalation Study with the Lewis Y Carbohydrate Specific Humanized Antibody IGN311

Oruzio, D. V., Waxenecker, G., Aulmann, C., Märkl, B., Wagner, T., Mudde, G. C., Schuster, M., Eller, N., Mayer, A., Stranner, S., et al. (2011) · Journal of Cancer Therapy · doi:10.4236/jct.2011.25102 · Cited by 6 · see citing works

Rituximab Serum Concentrations and Anti-Rituximab Antibodies During B-Cell Depletion Therapy for Myalgic Encephalopathy/Chronic Fatigue Syndrome

Rekeland, I. G., Fluge, Ø., Alme, K., Risa, K., Sørland, K., Mella, O., de Vries, A., & Schjøtt, J. D. (2018) · Clinical Therapeutics · doi:10.1016/j.clinthera.2018.10.019 · Cited by 6 · see citing works

Systemic Exposure of Rituximab Increased by Ibrutinib: Pharmacokinetic Results and Modeling Based on the HELIOS Trial

Lavezzi, S. M., de Jong, J., Neyens, M., Cramer, P., Demırkan, F., Fraser, G. A. M., Bartlett, N. L., Dilhuydy, M., Loscertales, J., Avigdor, A., et al. (2019) · Pharmaceutical Research · doi:10.1007/s11095-019-2605-8 · Cited by 6 · see citing works

Study of rituximab efficacy, cost, safety, and compliance of its package leaflet in a tertiary hospital

García, M., Feijoo, M. A. F., & Hernández, M. Á. C. (2009) · Farmacia Hospitalaria (English Edition) · doi:10.1016/s2173-5085(09)70094-2 · Cited by 5 · see citing works

Indications of plasma exchanges in combination with intravenous immunoglobulins or therapeutic monoclonal antibodies. How to combine them?

Vendramin, C., & Scully, M. (2019) · La Presse Médicale · doi:10.1016/j.lpm.2019.10.006 · Cited by 5 · see citing works

4. Antibody Therapy for Malignant Lymphoma

Tobinai, K. (2007) · Internal Medicine · doi:10.2169/internalmedicine.46.1782 · Cited by 5 · see citing works

Primary diffuse large B-cell lymphoma of the bone: bendamustine and rituximab are able to overcome resistant disease

Mondello, P., Mian, M., Arrigo, C., & Pitini, V. V. (2014) · SpringerPlus · doi:10.1186/2193-1801-3-342 · Cited by 4 · see citing works

37 Drugs that act on the immune system: cytokines and monoclonal antibodies

Vial, T., Descotes, J., Braun, F., & Behrend, M. (2007) · Side effects of drugs annual · doi:10.1016/s0378-6080(06)29037-8 · Cited by 3 · see citing works

Treatment of thrombotic thrombocytopenic purpura

Galstyan, G. M., Maschan, A., Евгеньевна, К. Е., & Калинина, И. И. (2021) · Terapevticheskii arkhiv · doi:10.26442/00403660.2021.06.200894 · Cited by 3 · see citing works

Rituximab dosing in hematological malignancies: an old question, revisited

Morcos, P. N., Boehnke, A., Valente, N., & Mager, D. E. (2019) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-019-03818-1 · Cited by 3 · see citing works

A Novel Class of On-Treatment Cancer Immunotherapy Biomarker: Trough Levels of Antibody Therapeutics in Peripheral Blood

Koguchi, Y., & Redmond, W. L. (2022) · Immunological Investigations · doi:10.1080/08820139.2022.2131570 · Cited by 3 · see citing works

Defining the Starting Dose: Should It Be mg/kg, mg/m2, or Fixed?

Gao, B., Klümpen, H., & Gurney, H. (2013) · Cancer drug discovery and develogment/Cancer drug discovery and development · doi:10.1007/978-1-4614-9135-4_4 · Cited by 2 · see citing works

Eight Cases of Gastrointestinal Malignant Lymphoma Required Surgery for Cicatricial Stenosis after Chemotherapy

Ishikawa, H., Amikura, K., Kawashima, Y., Sakamoto, H., Tanaka, Y., & Nishimura, Y. (2015) · Nihon Rinsho Geka Gakkai Zasshi (Journal of Japan Surgical Association) · doi:10.3919/jjsa.76.1362 · Cited by 2 · see citing works

Immunomonitoring du rituximab appliqué aux maladies auto-immunes : une aide pour la pratique clinique ?

Giraud, M., Cathébras, P. J., Roblin, X., Thibaudin, D., Lamure, S., Mariat, C., Paul, S., & Killian, M. (2021) · La Revue de Médecine Interne · doi:10.1016/j.revmed.2021.02.006 · Cited by 2 · see citing works

rHuPH20-Facilitated Subcutaneous Administration of Monoclonal Antibodies in Cancer Therapy

Dong, W., Chen, M., Wang, J., Xia, L., Wang, Q., Nie, X., Feng, Y., & Fang, Y. (2020) · Immunotherapy · doi:10.2217/imt-2020-0204 · Cited by 1 · see citing works

GLUCOCORTICOIDS AND DISEASE – MODIFYING ANTIRHEUMATIC DRUGS

(2010) · Elsevier eBooks · doi:10.1016/b978-0-444-53273-2.50007-9 · Cited by 1 · see citing works

Research Progress on Quantification Methods of Drug Concentration of Monoclonal Antibodies

Hu, L., Zhang, J., & Shao, H. (2022) · Current Pharmaceutical Analysis · doi:10.2174/1573412918666220329110712 · Cited by 1 · see citing works

Plasma Cetuximab Concentrations Correlate With Survival in Patients With Advanced KRAS Wild Type Colorectal Cancer

Jiang, D., Parshad, S., Zhan, L. J., Sim, H., Siu, L. L., Liu, G., Shapiro, J. D., Price, T. J., Jonker, D. J., Karapetis, C. S., et al. (2023) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2023.08.006 · Cited by 1 · see citing works

Biological therapy of B and T cell lymphoproliferative disorders

Dillman, R. O. (2009) · Springer eBooks · doi:10.1007/978-90-481-2289-9_27 · Cited by 1 · see citing works

Model-based design of rituximab dosing optimization in follicular non-hodgkin lymphoma

Ternant, D., Cartron, G., Hénin, É., Tod, M. M., Girard, P., & Paintaud, G. (2011) · HAL · Cited by 1 · see citing works

Impact of Diseases, Comorbidity, and Target Physiology on ADME, PK , and PK/PD of Therapeutic Biologics

Zheng, S., Wang, W., & Zhou, H. (2015) · Pharmaceutical Sciences Encyclopedia · doi:10.1002/9780470571224.pse545 · Cited by 1 · see citing works

A Retrospective Study of Efficacy and Toxicities of Rituximab in Combination with Chemotherapy for NHL patients in Bangladesh

Hoque, M. E., Karim, S., Hasan, M. N., & Siddiqui, M. M. R. (2015) · Anwer Khan Modern Medical College Journal · doi:10.3329/akmmcj.v6i1.24982

An update on90Y-ibritumomab tiuxetan in autologous stem cell transplantation

Gisselbrecht, C. (2009) · Hematology Meeting Reports (formerly Haematologica Reports) · doi:10.4081/hmr.v1i5.645

On behalf of the IDEC-C2B8 Japan Study Group

Tobinai, K., Igarashi, T., Itoh, K., Kobayashi, Y., Taniwaki, M., Ogura, M., Kinoshita, T., Hotta, T., & Division, H. (2004)

Eight weekly infusions of rituximab (R) for relapsed patients (pts) with indolent B-cell lymphoma mostly pretreated with R: A Japanese multicenter phase II study.

Igarashi, T., Murayama, K., Itoh, K., Kurosawa, M., Nagai, H., Watanabe, T., Tobinai, K., & IDEC-C2B8 Japan Study Group (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.15_suppl.e18510

Monoclonal Antibody Therapy for B-Cell Lymphoma: Clinical Trials of an Anti-CD20 Monoclonal Antibody for B-Cell Lymphoma in Japan

Tobinai, K. (2002) · International Journal of Hematology · doi:10.1007/bf02982806 · Cited by 24 · see citing works

A phase II Japanese trial of 90-minute rituximab infusion for untreated B-cell lymphoma

Saito, T., Nagai, H., Izutsu, K., Ando, K., Igarashi, T., Izumi, T., Ohashi, Y., Kamiyama, S., Ishizawa, K., & Tobinai, K. (2024) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyad193

Factors affecting toxicity, response and progression-free survival in relapsed patients with indolent B-cell lymphoma and mantle cell lymphoma treated with rituximab: a Japanese phase II study

Igarashi, T., Kobayashi, Y., Ogura, M., Kinoshita, T., Ohtsu, T., Sasaki, Y., MORISHIMA, Y., Murate, T., Kasai, M., Uike, N., et al. (2002) · Annals of Oncology · doi:10.1093/annonc/mdf155 · Cited by 139 · see citing works